Serina Therapeutics Reports $4.8 Million Net Loss, Focuses on SER-252 Development

Serina Therapeutics, Inc. reported a net loss of $4.8 million for the three months ending March 31, 2025, a significant improvement compared to a net loss of $15.0 million during the same period in 2024. The company did not generate any revenue during the latest quarter, a decrease from $5,000 in grant revenues reported in the prior year. Total operating expenses surged to $5.9 million, up from $2.3 million in the previous year, primarily driven by increased research and development costs, which rose to $3.0 million from $1.1 million, and general and administrative expenses, which increased to $2.9 million from $1.2 million.

The financial performance reflects a strategic shift following the merger with Legacy Serina, which was completed on March 26, 2024. This merger has positioned Serina as a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases. The company’s cash and cash equivalents stood at $4.3 million as of March 31, 2025, a slight increase from $3.7 million at the end of 2024. However, the company has expressed concerns regarding its ability to continue as a going concern, citing the need for additional capital to fund ongoing operations and development efforts.

Operationally, Serina has made significant strides in its research and development activities, particularly with its lead product candidate, SER-252 (POZ-apomorphine), which is aimed at treating Parkinson's disease. The company has entered into a partnership with Enable Injections, Inc. to develop and commercialize SER-252 in combination with Enable's enFuse® wearable drug delivery system. This collaboration is expected to enhance the delivery of the drug and is part of Serina's broader strategy to advance its product pipeline.

In terms of workforce, Serina has increased its employee headcount to support its development efforts, although specific numbers were not disclosed. The company anticipates that its expenses will continue to rise as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The management has indicated that it will rely on raising additional capital through equity offerings and other financing methods to sustain its operations and fund its research and development initiatives.

Looking ahead, Serina plans to submit an Investigational New Drug (IND) application for SER-252 in 2025 and expects to initiate a Phase 1 clinical trial. The company acknowledges the inherent risks and uncertainties associated with drug development and commercialization, emphasizing the need for ongoing funding to support its ambitious growth and development plans.